Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CPRXBullishCorporate Developmentsnews

High materiality8/10

Angelini Pharma to Acquire Catalyst Pharmaceuticals for $4.1 Billion

May 7, 2026, 2:17 AM EDT2 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The acquisition premium boosts shareholder confidence and reflects a strong valuation. Similar acquisitions in biotech have historically resulted in price appreciation post-announcement.

AI summary

What happened, with direct paths to the underlying reporting

Angelini Pharma has agreed to acquire Catalyst Pharmaceuticals for $31.50 per share, totaling around $4.1 billion. This transaction strengthens Angelini's position in the U.S. market for rare diseases, with expected closure in Q3 2026, providing immediate value for Catalyst shareholders.

Angelini Pharma acquires Catalyst Pharmaceuticals for $31.50 per share.
Transaction valued at approximately $4.1 billion, with a 28% premium.
Acquisition to strengthen Angelini's U.S. presence in rare diseases.
Closing expected in Q3 2026, marking Angelini's U.S. market entry.
Catalyst's products include FIRDAPSE and AGAMREE for rare diseases.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Angelini Pharma to Acquire Catalyst Pharmaceuticals for $4.1 Billion

Angelini completes Catalyst deal; CPRX shareholders receive $31.50 cash per share

Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues

Top 10% Biotech Stock Catalyst Pharma Doubles Wall Street's Profit Views

Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth